Sugi Predict

Sugi Predict / Compounds / SCHEMBL907623

SCHEMBL907623

SCHEMBL907623

CCOC(=O)C1CCNC1=O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ POLB P06746 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ TLR4 O00206 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TSHR P16473 1/20 0.40
▸ PPM1B O75688 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ PPP1CC P36873 1/20 0.40
▸ ACACB O00763 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27405623 1.00 MAPT (0.45) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL74445 0.90 L3MBTL1 (0.50) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL940890 0.84 L3MBTL1 (0.45) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL11489301 0.83 MAPT (0.46) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL9782199 0.81 MAPT (0.47) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL8826699 0.81 FKBP5 (0.43) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL3193620 0.81 L3MBTL1 (0.42) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL21662208 0.79 L3MBTL1 (0.41) ALDH1A1HSD17B10POLBPPM1BPTPN1
SCHEMBL43971 0.79 L3MBTL1 (0.41) ALDH1A1HSD17B10POLBPPM1BPTPN1
SCHEMBL11498167 0.78 L3MBTL1 (0.35) MAPTALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115677551-A Preparation process of 2-oxopyrrolidine-3-ethyl formate 武汉市振邦生物科技有限公司 2023-02-03 — — CN claimed
EP-3237903-B1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RES & ENG CO (US) 2020-02-26 — — EP claimed
EP-3237903-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS Exxonmobil Research And Engineering Company (US) 2017-11-01 — — EP claimed
US-20160187314-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 — — US claimed
WO-2016106211-A1 METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 — — WO claimed
US-20160187315-A1 METHODS FOR DETERMINING CONDITION AND QUALITY OF PETROLEUM PRODUCTS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2016-06-30 — — US claimed
US-20100163070-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBRES USING HEATING MEANS AND AN AMIDE L'OREAL S.A. (FR) 2010-07-01 — — US claimed
EP-4741397-A1 FUSED TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shenzhen Zhongge Biological Technology Co., Ltd. (CN) 2026-05-13 — — EP disclosed
WO-2025129135-A2 COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-06-19 — — WO disclosed
US-12208088-B2 Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof GENENTECH, INC. (US) 2025-01-28 — — US disclosed
WO-2025011457-A1 FUSED TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 深圳众格生物科技有限公司 2025-01-16 — — WO disclosed
CN-118574834-A Fused tetracyclic compounds, compositions and uses thereof 泰博生物科技股份有限公司 2024-08-30 — — CN disclosed
US-20240208942-A1 METAP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF CANWELL BIOTECH LTD (CN) 2024-06-27 — — US disclosed
WO-2009124166-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK & CO., INC. (US) 2009-10-08 — — WO disclosed
WO-2009123870-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK & CO., INC. (US) 2009-10-08 — — WO disclosed
EP-2032538-A2 QUINOLINE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2009-03-11 — — EP disclosed
US-20090030195-A1 1-(2H)-ISOQUINOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-01-29 — — US disclosed
WO-2007146824-A2 QUINOLINE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-12-21 — — WO disclosed
EP-1854792-A1 1-(2H)-ISOQUINOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-11-14 — — EP disclosed
US-4578378-A (Oxoheterocyclic carbonamido)cephem carboxylic acid derivatives SHIONOGI & CO., LTD. (JP) 1986-03-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12208088-B2 Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof HIPK1, NEK1, HIPK2 MAPT 4740/4885ALDH1A1 2398/4885MEN1 1717/4885
US-20240208942-A1 METAP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF METAP2, METAP1, MTX2 MAPT 1037/4885ALDH1A1 3294/4885MEN1 802/4885
US-20090030195-A1 1-(2H)-ISOQUINOLONE DERIVATIVE NQO1, NR5A1, SRD5A1 MAPT 4671/4885ALDH1A1 371/4885MEN1 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.